Welcome to Genelux Corporation
“Transforming cancer from a terminal disease to a manageable condition.”
Genelux Corporation is a privately-held biomedical company whose mission is to develop safe and
effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there
is no effective treatment today.
The flagship Genelux technology utilizes an attenuated live virus to diagnose and treat cancer without
harming healthy cells in the body. A Phase I clinical trial of GL-ONC1, the company’s first product candidate
for the treatment of cancer, is currently underway in the United Kingdom. Additional clinical trials are in
regulatory preparation and/or submission stages.